- |||||||||| fingolimod / Generic mfg.
Journal: FTY720 Suppresses Pathogenic Retinal M (Pubmed Central) - Apr 5, 2024
This study suggests that in an HG-induced rMC-1 cell model, FTY720 significantly inhibited the production of inflammatory cytokines by inhibiting mTOR/NF-?B signaling and regulating autophagy. These findings were associated with a decrease in rMC-1 cell injury, suggesting that FTY720 or related compounds may be valuable modulators of HG-induced retinal injury.
- |||||||||| Velsipity (etrasimod) / Pfizer
Trial completion date, Trial primary completion date: ELEVATE UC OLE: An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Apr 4, 2024
P3, N=912, Recruiting,
Thus, multiple ascending doses of etrasimod were not associated with clinically relevant QT/QTc effects in healthy adults and only had a mild, transient, and asymptomatic impact on heart rate. Trial completion date: Jan 2027 --> Jul 2026 | Trial primary completion date: Jan 2027 --> Jul 2026
- |||||||||| Velsipity (etrasimod) / Pfizer
Enrollment closed, Phase classification, Enrollment change, Trial completion date, Trial primary completion date: A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection (clinicaltrials.gov) - Apr 2, 2024
P3, N=53, Active, not recruiting,
Different metabolic profiles characterize antigen-specific-T and -B cell response in fingolimod- and natalizumab-treated patients, whose immune response differs from all the other MS treatments. Recruiting --> Active, not recruiting | Phase classification: P2/3 --> P3 | N=400 --> 53 | Trial completion date: Sep 2026 --> Apr 2024 | Trial primary completion date: Sep 2026 --> Apr 2024
- |||||||||| Remicade (infliximab) / J&J, Velsipity (etrasimod) / Pfizer, Rinvoq (upadacitinib) / AbbVie
Retrospective data, Review, Journal: Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis. (Pubmed Central) - Apr 2, 2024
For maintenance treatment, in moderate to severe UC, this NWM showed that upadacitinib 30?mg/day and etrasimod 2?mg/day were ranked best for efficacy in re-randomized and treat-through patients respectively. Tofacitinib 10?mg/day and infliximab 3.5?mg/Kg Q8W showed the best efficacy-safety therapeutic profile in re-randomized and treat-through patients respectively.
- |||||||||| Velsipity (etrasimod) / Pfizer
Review, Journal: Etrasimod: First Approval. (Pubmed Central) - Apr 1, 2024
Clinical development of etrasimod for use in the treatment of Crohn's disease, atopic dermatitis, eosinophilic oesophagitis and alopecia areata is ongoing worldwide. This article summarises the milestones in the development of etrasimod leading to this first approval for the treatment of ulcerative colitis in adults.
- |||||||||| Tysabri (natalizumab) / Biogen, Royalty
Review, Journal: Concurrent glioma and multiple sclerosis: A systematic review of case reports. (Pubmed Central) - Apr 1, 2024
An interdisciplinary approach, combining the expertise of neurologists, oncologists, radiologists, and pathologists, is vital to ensure accurate diagnosis and optimal management of affected individuals. Nonetheless, there is still a significant lack of information regarding this phenomenon, necessitating large-scale population-based studies and experimental research.
- |||||||||| Zeposia (ozanimod) / BMS
Practical Guidelines and Long-term Experience on ZEPOSIA in Treatment of UC (Room A) - Mar 30, 2024 - Abstract #IMKASID2024IMKASID_168;
Notably, the non-CDED group improved weight z-scores more during induction therapy. This highlights the need for healthcare providers to monitor and address malnutrition in pediatric CD patients for their well-being.
- |||||||||| Zeposia (ozanimod) / BMS
ZEPOSIA, a First in Class S1PR Modulator with Proven Clinical Efficacy (Room A) - Mar 30, 2024 - Abstract #IMKASID2024IMKASID_167;
In conclusion, ozanimod is an oral therapy for moderate to severe UC, offering rapid symptomatic relief, significant improvements in clinical remission and mucosal healing, and sustained efficacy over time. Its selective mechanism of ac tion and favorable safety profile position it as a promising first -line advanced therapy option after conventional treatments, addressing the unmet needs of patients with UC.
- |||||||||| Zeposia (ozanimod) / BMS
Summary of New Agents for IBD - Ozanimod (Room C) - Mar 30, 2024 - Abstract #IMKASID2024IMKASID_75;
Among these, upadacitinib and filgotinib emerged as selective JAK1 inhibitors, offering promise in conditions like ulcerative colitis (UC)...It also details the nature and frequency of monitoring during treatment, which should be adapted to the individual patient based on pre-existing risk factors and events that possibly occur during treatment. This review also provides insights into the patient characteristics and clinical scenarios best suited for ozanimod treatment, based on its efficacy, safety profile, and risks compared with other therapies.
- |||||||||| Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
Summary of New Agents for IBD - Filgotinib (Room C) - Mar 30, 2024 - Abstract #IMKASID2024IMKASID_74;
Among these, upadacitinib and filgotinib emerged as selective JAK1 inhibitors, offering promise in conditions like ulcerative colitis (UC)...It also details the nature and frequency of monitoring during treatment, which should be adapted to the individual patient based on pre-existing risk factors and events that possibly occur during treatment. This review also provides insights into the patient characteristics and clinical scenarios best suited for ozanimod treatment, based on its efficacy, safety profile, and risks compared with other therapies.
- |||||||||| The Era of Small Molecules: Good Things Come in Small Packages (Room A) - Mar 30, 2024 - Abstract #IMKASID2024IMKASID_66;
Following tofacitinib, filgotinib and upadacitinib were also introduced as JAK inhibitors for the treatment of ulcerative colitis...Ozanimod was the first S1PR modulator approved for the treatment o f ulcerative colitis in the United States and Europe, followed by the approval of etrasimod in Europe for the same indication...In Jap an, the oral ?4 inhibitor carotegrast methyl is also available for the treatment of ulcerative colitis...They also lack antigenicity, offering the possibility of drug holidays. On the other hand, the development of biomarkers to predict the effectiveness of the numerous molecular targeted therapies, including biologics, for individu al patients is urgently needed.
- |||||||||| Journal: Prediction of disease activity and treatment failure in relapsing-remitting MS patients initiating daily oral DMTs. (Pubmed Central) - Mar 29, 2024
Notably, 218 patients (62.4% females) initiating dimethyl fumarate, teriflunomide, and fingolimod were included...RS, mRS, and MAGNIMS 0 categories showed significantly lower EDA and treatment failure than the remainder. Scoring systems present different predictive abilities for disease activity parameters at 36?months in MS patients initiating daily oral therapies, warranting further adjustments (i.e. introduction of fluid biomarkers) to depict disease activity status fully.
- |||||||||| fingolimod / Generic mfg.
Autoimmune CD4 T cell exhaustion is counteracted by peripheral circulating T cell population with stem-like potential (Exhibit Hall F1; Poster Board Number: B747) - Mar 29, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_2099;
Blockade of T cell entry with FTY720 reduced T cell numbers in the tissue, and protected NOD mice from diabetes...Similarly, BDC2.5 islet antigen specific T cells circulating in peripheral non-draining lymphoid organs exhibit phenotypic and epigenetic signature of pre-primed, but largely undifferentiated T cells. Collectively, our data indicates that autoimmune CD4 T cell persistence is sustained through continuous recruitment of new T cells from circulating non-differentiated stem-like compartment.
- |||||||||| fingolimod / Generic mfg.
Development of CD4+ memory T cells in periodontal health and disease (Exhibit Hall F1; Poster Board Number: B178) - Mar 29, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_1821;
FTY720 didn't prevent bone loss but reduced CD45+ infiltration and increased gingival CD4+ memory cell frequency. Imaging Mass Cytometry in PD biopsies revealed increased CD4+CD45RO+ cells versus healthy controls, concentrated near innate cells along the subepithelial zone.
- |||||||||| fingolimod / Generic mfg.
High-dose mIL-2/CD25 and PD-1 blockade induces local expansion of distinctive tumor-specific CD8+ T effector cells (Exhibit Hall F1; Poster Board Number: B142) - Mar 29, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_723;
CD8+ T cells in the TME of FTY720- and mIL-2/CD25-treated mice expanded and exhibited antitumor activity at comparable levels to mice that received only mIL-2/CD25. Together, these data suggest that mIL-2/CD25 acts within the TME to readily support the expansion of unique CD8+ tumor-reactive T effector cells while minimally affecting intratumoral Tregs.
- |||||||||| vibozilimod (SCD-044) / Sun Pharma
Trial completion date, Trial primary completion date: SOLARES-PsO-1: To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Mar 27, 2024
P2, N=240, Recruiting,
These findings suggest differential effects of fingolimod on peripheral and central neuropathy in twitcher mice, which may explain its modest efficacy on behavior and lifespan. Trial completion date: Apr 2024 --> Nov 2024 | Trial primary completion date: Feb 2024 --> Aug 2024
- |||||||||| fingolimod / Generic mfg.
Journal: Neutrophil Membrane-Camouflaged Polyprodrug Nanomedicine for Inflammation Suppression in Ischemic Stroke Therapy. (Pubmed Central) - Mar 23, 2024
Fingolimod hydrochloride (FTY720) is an FDA-approved anti-inflammatory drug which exhibits potential neuroprotective effects in ischemic brain parenchyma...In addition, single-cell RNA-sequencing analysis identifies that the nanomedicine attenuates post-stroke inflammation by reprogramming microglia toward anti-inflammatory phenotypes, which is realized via modulating Cebpb-regulated activation of NLRP3 inflammasomes and secretion of CXCL2 chemokine. This study offers new insights into the design and fabrication of polyprodrug nanomedicines for effective suppression of inflammation in ischemic stroke therapy.
- |||||||||| fingolimod / Generic mfg., itraconazole / Generic mfg.
Unveiling the Enigma: Histoplasma-Mediated Hypercalcemia () - Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_808;
Delay in diagnosis can be fatal if not treated appropriately. Hypercalcemia due to histoplasmosis may not respond to traditional therapies.
- |||||||||| fingolimod / Generic mfg.
Autoimmune CD4 T cell exhaustion is counteracted by peripheral circulating T cell population with stem-like potential (Room W184) - Mar 22, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_554;
Blockade of T cell entry with FTY720 reduced T cell numbers in the tissue, and protected NOD mice from diabetes...Similarly, BDC2.5 islet antigen specific T cells circulating in peripheral non-draining lymphoid organs exhibit phenotypic and epigenetic signature of pre-primed, but largely undifferentiated T cells. Collectively, our data indicates that autoimmune CD4 T cell persistence is sustained through continuous recruitment of new T cells from circulating non-differentiated stem-like compartment.
- |||||||||| Clinical, Retrospective data, Review: Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis. (Pubmed Central) - Mar 21, 2024
This risk is higher in MS treatment, and specifically during long-term natalizumab therapy. While this drug is still routinely prescribed in this field, considering the efficacy in reducing MS relapses, in other areas it could play a smaller role, and be gradually replaced by other safer and more recently approved agents.
- |||||||||| Zeposia (ozanimod) / BMS, Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
Journal: IBD in women of reproductive age: where do novel therapies fit in? (Pubmed Central) - Mar 20, 2024
While this drug is still routinely prescribed in this field, considering the efficacy in reducing MS relapses, in other areas it could play a smaller role, and be gradually replaced by other safer and more recently approved agents. No abstract available
- |||||||||| fingolimod / Generic mfg.
Journal: Synthesis and Biophysical Characterization of Fingolimod Derivatives as Cardiac Troponin Antagonists. (Pubmed Central) - Mar 20, 2024
Here we investigate the structure-activity relationship of the fingolimod hydrophobic headgroup and show that increasing the alkyl chain length increases both its affinity for NcTnC and its inhibitory effect on the NcTnC-cTnISP interaction and that decreasing flexibility completely abolishes these effects. Strikingly, the longer derivatives have no effect on the calcium affinity of cTnC, suggesting that they act as better inhibitors.
- |||||||||| fingolimod / Generic mfg.
A CASE OF FINGOLIMOD-ASSOCIATED MACULAR EDEMA (FAME) () - Mar 18, 2024 - Abstract #COPHyEU2024COPHY_EU_230;
Treatment was initiated with oral acetazolamide, steroid and NSAIDs drops. To highlight the necessity of taking a thorough patient's medical history and the importance of the collaboration between Neurologists and Ophthalmologists.
- |||||||||| fingolimod / Generic mfg.
Journal: An integrative mechanistic model of thymocyte dynamics. (Pubmed Central) - Mar 16, 2024
We performed model sensitivity analyses to reveal potential therapeutic targets through an identification of processes critically affecting thymic function; we further explored differences in thymic function across healthy subjects, multiple sclerosis patients, and patients on fingolimod treatment...In summary, the proposed model accurately describes, in mechanistic terms, thymic output as a function of age. It may be further used to perform predictive simulations of clinically relevant scenarios which combine specific patho-physiological conditions and pharmacological interventions of interest.
- |||||||||| Omvoh (mirikizumab) / Eli Lilly
Journal: Mirikizumab (Omvoh) for ulcerative colitis. (Pubmed Central) - Mar 15, 2024
Lung function also showed improvement of airway hyperreactivity to methacholine challenge following fingolimod therapy. No abstract available
|
